- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00043082
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Compare overall survival of patients with platinum-sensitive recurrent ovarian epithelial or primary peritoneal cancer treated with carboplatin with or without pegylated doxorubicin HCl liposome.
- Compare progression-free survival, confirmed complete response rates, and time to treatment failure in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease measurability (elevated CA 125 only vs nonmeasurable disease only with or without elevated CA 125 vs measurable disease), number of disease sites (2 or fewer vs 3 or more), and serous tumor histology (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive carboplatin IV over 15 minutes and pegylated doxorubicin HCl liposome IV over 1 hour on day 1.
- Arm II: Patients receive carboplatin IV as in arm I. Treatment in both arms repeats every 4 weeks for a total of 15 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 4 weeks, every 6 months for 3 years, and then annually for 7 years.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study within 4 years.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36607
- MBCCOP - Gulf Coast
-
-
Arizona
-
Phoenix, Arizona, United States, 85006-2726
- CCOP - Western Regional, Arizona
-
Phoenix, Arizona, United States, 85012
- Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
-
Tucson, Arizona, United States, 85723
- Veterans Affairs Medical Center - Tucson
-
Tucson, Arizona, United States, 85724
- Arizona Cancer Center at University of Arizona Health Sciences Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
Little Rock, Arkansas, United States, 72205
- Veterans Affairs Medical Center - Little Rock
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Fresno, California, United States, 93720
- California Cancer Center at Woodward Park Office
-
Loma Linda, California, United States, 92357
- Veterans Affairs Medical Center - Loma Linda (Pettis)
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, United States, 90033
- USC/Norris Comprehensive Cancer Center and Hospital
-
Martinez, California, United States, 94553
- Veterans Affairs Outpatient Clinic - Martinez
-
Oakland, California, United States, 94609-3305
- CCOP - Bay Area Tumor Institute
-
Orange, California, United States, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
Sacramento, California, United States, 95817
- University of California Davis Cancer Center
-
Santa Rosa, California, United States, 95403
- CCOP - Santa Rosa Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
Denver, Colorado, United States, 80220
- Veterans Affairs Medical Center - Denver
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20060
- MBCCOP - Howard University Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- Veterans Affairs Medical Center - Tampa (Haley)
-
-
Georgia
-
Atlanta, Georgia, United States, 30342-1701
- CCOP - Atlanta Regional
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Veterans Affairs Medical Center - Chicago (Westside Hospital)
-
Chicago, Illinois, United States, 60612
- MBCCOP - University of Illinois at Chicago
-
Decatur, Illinois, United States, 62526
- CCOP - Central Illinois
-
Hines, Illinois, United States, 60141
- Veterans Affairs Medical Center - Hines
-
Maywood, Illinois, United States, 60153-5500
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
-
Kansas
-
Kansas City, Kansas, United States, 66160-7353
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
Wichita, Kansas, United States, 67214-3882
- CCOP - Wichita
-
Wichita, Kansas, United States, 67218
- Veterans Affairs Medical Center - Wichita
-
-
Kentucky
-
Lexington, Kentucky, United States, 40502-2236
- Veterans Affairs Medical Center - Lexington
-
Lexington, Kentucky, United States, 40536-0084
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Veterans Affairs Medical Center - New Orleans
-
New Orleans, Louisiana, United States, 70112
- MBCCOP - LSU Health Sciences Center
-
New Orleans, Louisiana, United States, 70112
- Tulane Cancer Center at Tulane University Hospital and Clinic
-
Shreveport, Louisiana, United States, 71130-3932
- Louisiana State University Health Sciences Center - Shreveport
-
Shreveport, Louisiana, United States, 71101-4295
- Veterans Affairs Medical Center - Shreveport
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Cancer Research Center at Boston Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Ann Arbor, Michigan, United States, 48109-0948
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, United States, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, United States, 48201-1932
- Veterans Affairs Medical Center - Detroit
-
Detroit, Michigan, United States, 48202
- Josephine Ford Cancer Center at Henry Ford Health System
-
Grand Rapids, Michigan, United States, 49503
- CCOP - Grand Rapids
-
Royal Oak, Michigan, United States, 48073-6769
- CCOP - Beaumont
-
Southfield, Michigan, United States, 48075
- Providence Cancer Institute at Providence Hospital - Southfield
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216-4505
- University of Mississippi Medical Center
-
Jackson, Mississippi, United States, 39216
- Veterans Affairs Medical Center - Jackson
-
-
Missouri
-
Kansas City, Missouri, United States, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, United States, 63141
- CCOP - St. Louis-Cape Girardeau
-
Saint Louis, Missouri, United States, 63110
- St. Louis University Hospital Cancer Center
-
Springfield, Missouri, United States, 65807
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108-5138
- Veterans Affairs Medical Center - Albuquerque
-
Albuquerque, New Mexico, United States, 87131
- MBCCOP - University of New Mexico HSC
-
-
New York
-
New York, New York, United States, 10016
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
Rochester, New York, United States, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Goldsboro, North Carolina, United States, 27534-9479
- CCOP - Southeast Cancer Control Consortium
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220-2288
- Veterans Affairs Medical Center - Cincinnati
-
Cincinnati, Ohio, United States, 45267-0501
- Charles M. Barrett Cancer Center at University Hospital
-
Cleveland, Ohio, United States, 44195-9001
- Cleveland Clinic Taussig Cancer Center
-
Columbus, Ohio, United States, 43206
- CCOP - Columbus
-
Dayton, Ohio, United States, 45429
- CCOP - Dayton
-
Dayton, Ohio, United States, 45428-1002
- Veterans Affairs Medical Center - Dayton
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97207
- Veterans Affairs Medical Center - Portland
-
Portland, Oregon, United States, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, United States, 97201-3098
- Cancer Institute at Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Charleston, South Carolina, United States, 29401-5799
- Veterans Affairs Medical Center - Charleston
-
Greenville, South Carolina, United States, 29615
- CCOP - Greenville
-
Spartanburg, South Carolina, United States, 29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Veterans Affairs Medical Center - Memphis
-
Memphis, Tennessee, United States, 38104
- University of Tennessee Cancer Institute at Methodist Central Hospital
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Harrington Cancer Center
-
Amarillo, Texas, United States, 79106
- Veterans Affairs Medical Center - Amarillo
-
Fort Sam Houston, Texas, United States, 78234-6200
- Brooke Army Medical Center
-
Galveston, Texas, United States, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, United States, 77030-4095
- University of Texas - MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229-3900
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, United States, 78229
- Veterans Affairs Medical Center - San Antonio (Murphy)
-
Temple, Texas, United States, 76504
- Veterans Affairs Medical Center - Temple
-
Temple, Texas, United States, 76508
- CCOP - Scott and White Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84148
- Veterans Affairs Medical Center - Salt Lake City
-
Salt Lake City, Utah, United States, 84112-5550
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98101
- CCOP - Virginia Mason Research Center
-
Seattle, Washington, United States, 98108
- Veterans Affairs Medical Center - Seattle
-
Seattle, Washington, United States, 98109
- Puget Sound Oncology Consortium
-
Tacoma, Washington, United States, 98405-0986
- CCOP - Northwest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed ovarian epithelial carcinoma
- Stage III or IV disease at time of initial staging laparotomy
- Primary peritoneal and mixed Mullerian tumors allowed
- No borderline ovarian tumors
- Disease progression or recurrence after a progression-free and platinum-free interval of 6-24 months after completion of first-line platinum-based chemotherapy (either single agent or combination therapy)
Disease progression or recurrence based solely on CA 125 elevation allowed, provided that one of the following is true:
- Prior baseline CA 125 greater than 35 U/mL and subsequent normalization of no greater than 35 U/mL must have CA 125 greater than 2 times upper limit of normal (ULN) on 2 occasions at least 1 week apart
- Prior baseline CA 125 greater than 35 U/mL that never normalized must have CA 125 greater than 2 times the nadir value on 2 occasions at least 1 week apart
- Prior normal baseline CA 125 (no greater than 35 U/mL) must show CA 125 greater than 2 times ULN on 2 occasions at least 1 week apart
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 10 g/dL
Hepatic
- SGOT and/or SGPT no greater than 2 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 2 times ULN
- Bilirubin no greater than ULN
Renal
- Creatinine no greater than 1.9 mg/dL
Cardiovascular
- No New York Heart Association class II-IV cardiac disease
- No clinical evidence of congestive heart failure
- Ejection fraction greater than 50% by MUGA or 2-dimensional echocardiogram
Other
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or incidental carcinoid cancer
- No evidence of active or uncontrolled infection
- No severe gastrointestinal symptoms (i.e., partial obstruction) and/or gastrointestinal bleeding or diarrhea
- No greater than grade 1 preexisting sensory neuropathy
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 28 days since prior biologic consolidation therapy
- No concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- At least 28 days since prior non-platinum-containing consolidation chemotherapy
- No prior pegylated doxorubicin HCl liposome
- No prior cumulative anthracycline (e.g., doxorubicin, daunorubicin, epirubicin) dose in excess of 240 mg/m^2
- No other concurrent chemotherapy
Endocrine therapy
- No concurrent hormonal therapy
Radiotherapy
- No prior abdominopelvic irradiation
- No concurrent radiotherapy
Surgery
- See Disease Characteristics
- At least 28 days since prior surgical debulking for disease progression or recurrence and recovered
- No concurrent surgery
Other
- No other prior treatment during the 6-24 month progression-free and platinum-free interval except up to 12 courses of consolidation therapy
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: carboplatin and doxorubicin
carboplatin and liposomal doxorubicin given q 4 weeks
|
intravenous q 4 weeks
intravenous q 4 weeks
|
Active Comparator: carboplatin
carboplatin alone
|
intravenous q 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: ten years
|
From date of registration to date of death
|
ten years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival and response
Time Frame: 10 years
|
response by RECIST criteria
|
10 years
|
side effects
Time Frame: 15 months
|
side effects described per NCI CTC version 2.0
|
15 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: David S. Alberts, MD, University of Arizona
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Carboplatin
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- CDR0000256331
- U10CA032102 (U.S. NIH Grant/Contract)
- S0200 (Other Identifier: SWOG)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Cancer
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Eve RodlerNot yet recruitingBreast Cancer | Ovarian Cancer | Breast Neoplasm | Breast Carcinoma | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Invasive Breast Cancer | Cancer, Breast | Breast Cancer Stage III | Ovary Cancer | Malignant Tumor of Breast | Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV | Ovarian Cancer... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
Clinical Trials on carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
-
Medical Research CouncilEuropean Organisation for Research and Treatment of Cancer - EORTCCompletedTesticular Germ Cell TumorUnited Kingdom, Canada, Norway, Netherlands, South Africa, Brazil, Finland